A Study of LY2775240 in Healthy Participants

Sponsor
Eli Lilly and Company
Study ID
NCT02963779
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY2775240 — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally
  • Apremilast — DRUG
    Administered orally

Study Details

This study is conducted to determine the side effects related to LY2775240 given orally to healthy participants. Blood tests will be done to check how much LY2775240 is absorbed into the bloodstream and how long the body takes to get rid of it. Each participant will enroll in either Part A or Part B of the study, which will last about 14 weeks and 8 weeks respectively, including screening.

Key Dates

First listed
Nov 15, 2016
Start date
Dec 31, 2016
Status verified
Nov 2017
Primary completion
Oct 5, 2017
Completion
Oct 5, 2017

Study Design

Enrollment
35 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY2775240 (Part A)
    Escalating oral doses of LY2775240 administered in healthy participants
  • Experimental: LY2775240 (Part B)
    Oral dose of LY2775240 in healthy participants
  • Placebo Comparator: Placebo (Part A)
    Placebo administered orally in healthy participants
  • Active Comparator: Apremilast (Part B)
    Oral dose of apremilast in healthy participants

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through to final follow-up at approximately Week 14 ]

Related Studies